Genscript Biotech Corporation
Genscript Biotech Corporation, a leading player in the biotechnology industry, is headquartered in China (CN) and operates extensively across North America, Europe, and Asia. Founded in 2002, Genscript has established itself as a pioneer in gene synthesis, peptide synthesis, and antibody development, catering to a diverse range of sectors including pharmaceuticals, diagnostics, and academic research. The company’s core offerings, such as its innovative gene editing tools and custom protein services, are distinguished by their high quality and rapid turnaround times. Genscript's commitment to advancing life sciences has earned it a prominent market position, with notable achievements including numerous collaborations with top-tier research institutions and a robust portfolio of intellectual property. As a trusted partner in biotechnological advancements, Genscript continues to drive innovation and support scientific discovery globally.
DitchCarbon Score
How does Genscript Biotech Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genscript Biotech Corporation's score of 35 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Genscript Biotech Corporation's reported carbon emissions
Genscript Biotech Corporation, headquartered in China, has made significant commitments towards reducing its carbon emissions, although specific emissions data for the most recent year is currently unavailable. The company has set ambitious targets as part of its climate strategy, aiming for net-zero greenhouse gas emissions across all scopes by 2050. In the near term, Genscript has committed to reducing absolute Scope 1 and 2 greenhouse gas emissions by approximately 54.6% by 2033, using 2023 as the baseline year. Additionally, the company plans to cut absolute Scope 3 emissions—specifically from fuel and energy-related activities and waste generated in operations—by about 32.5% within the same timeframe. Furthermore, Genscript aims for 83% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by 2029. For the long term, Genscript has set a target to reduce absolute Scope 1 and 2 emissions by 90% by 2050, alongside a similar 90% reduction in Scope 3 emissions. These commitments align with industry standards and reflect the company's dedication to addressing climate change and promoting sustainability within its operations and supply chain.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genscript Biotech Corporation is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
